Online first
Research paper
Published online: 2024-09-25
Association between Elevated Liver Enzymes and Microvascular Complications in Patients with Type 2 Diabetes: The PERSIAN Guilan Cohort Study
1
, 2, 2, 3, 24, 5, 1, 2
, 2, 2, 3, 24, 5, 1, 2
Abstract
Objective: The present study investigated the association between increased serum levels of liver enzymes and the risk of diabetic microvascular complications among Prospective Epidemiological Research Studies in IRAN (PERSIAN) Guilan Cohort Study (PGCS) population. Materials and methods: In this cross-sectional study, 403 patients with T2D from PGCS were included. Patients’ demographic, anthropometric, and clinical characteristics were assessed using a questionnaire. Urine analysis and blood laboratory tests were conducted to assess diabetic nephropathy and serum liver enzyme levels. Fundus photometry and the Michigan Neuropathy Screening Instrument (MNSI) were used to assess retinopathy and neuropathy, respectively. All statistical analyses were performed using SPSS version 16.0, and the significant level was p < 0.05. Results: Of 403 patients with diabetes, 202 (50.1%) were male, and the mean age of participants was 59.67 ± 6.33 years. No statistically significant association between the increased level of liver enzymes and developing retinopathy or neuropathy in patients with diabetes was observed (p > 0.05). However, increased levels of gamma-glutamyl transferase (GGT) were significantly associated with the development of diabetic nephropathy (OR = 3.42, 95% CI, 1.28–6.00, p = 0.014). No statistically significant association was observed between increased levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) and diabetic nephropathy (p > 0.05). Conclusions: The results of the study suggested increased levels of GGT as an independent risk factor for the development of nephropathy in patients with diabetes.
Keywords: diabetes mellitusliver enzymeretinopathyneuropathynephropathy
References
- Zhang L, Long J, Jiang W, et al. Trends in Chronic Kidney Disease in China. N Engl J Med. 2016; 375(9): 905–906.
- Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina. 2006; 26(6 Suppl): S71–S79.
- Lin YC, Chang YH, Yang SY, et al. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018; 117(8): 662–675.
- Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136–154.
- Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6): 330–344.
- Viswanathan V, Kadiri M, Medimpudi S, et al. Association of non-alcoholic fatty liver disease with diabetic microvascular and macrovascular complications in South Indian diabetic subjects. International Journal of Diabetes in Developing Countries. 2010; 30(4): 208.
- Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6): 1286–1292.
- Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol. 2006; 40(7): 633–635.
- Hossain IA, Shah MMR, Rahman MK, et al. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr. 2016; 10(1 Suppl 1): S25–S29.
- Deravi N, Dehghani Firouzabadi F, Moosaie F, et al. Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study. Front Endocrinol (Lausanne). 2023; 14: 1147458.
- Bi Y, Liu Y, Wang H, et al. The association of alanine aminotransferase and diabetic microvascular complications: A Mendelian randomization study. Front Endocrinol (Lausanne). 2023; 14: 1104963.
- Afarideh M, Aryan Z, Ghajar A, et al. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes. 2019; 13(6): 505–514.
- Yanagawa T, Koyano K, Azuma K. Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression. Diabetol Int. 2021; 12(3): 268–276.
- Mansour-Ghanaei F, Joukar F, Naghipour MR, et al. The PERSIAN Guilan Cohort Study (PGCS). Arch Iran Med. 2018; 22(1): 39–45.
- Poustchi H, Eghtesad S, Kamangar F, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design. Am J Epidemiol. 2018; 187(4): 647–655.
- Adiga US, Malawadi BN. Association of Diabetic Nephropathy and Liver Disorders. J Clin Diagn Res. 2016; 10(10): BC05–BC07.
- Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17(11): 1281–1289.
- Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996; 49(12): 1373–1379.
- Maroufizadeh S, Almasi-Hashiani A, Hosseini M, et al. Prevalence of diabetic retinopathy in Iran: a systematic review and Meta-analysis. Int J Ophthalmol. 2017; 10(5): 782–789.
- Moradi Y, Baradaran HR, Djalalinia S, et al. Complications of type 2 diabetes in Iranian population: An updated systematic review and meta-analysis. Diabetes Metab Syndr. 2019; 13(3): 2300–2312.
- Teo ZL, Tham YC, Yu M, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021; 128(11): 1580–1591.
- Rabieenia E, Jalali R, Mohammadi M. Prevalence of nephropathy in patients with type 2 diabetes in Iran: A systematic review and meta-analysis based on geographic information system (GIS). Diabetes Metab Syndr. 2020; 14(5): 1543–1550.
- Mohammadi M, Raiegani AA, Jalali R, et al. The prevalence of retinopathy among type 2 diabetic patients in Iran: A systematic review and meta-analysis. Rev Endocr Metab Disord. 2019; 20(1): 79–88.
- Aliabadi DA, Moradian N, Rahmanian E, et al. Prevalence of neuropathy in patients with type 2 diabetes in Iran : A systematic review and meta-analysis. Wien Klin Wochenschr. 2021; 133(5-6): 222–228.
- Bulum T, Tomić M, Duvnjak L. Serum bilirubin levels are negatively associated with diabetic retinopathy in patients with type 1 diabetes and normal renal function. Int Ophthalmol. 2018; 38(3): 1095–1101.
- Zhang GH, Yuan TH, Yue ZS, et al. The presence of diabetic retinopathy closely associated with the progression of non-alcoholic fatty liver disease: A meta-analysis of observational studies. Front Mol Biosci. 2022; 9: 1019899.
- Greco C, Nascimbeni F, Carubbi F, et al. Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Peripheral Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10(19).
- Kim K, Oh TJ, Cho HC, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep. 2021; 11(1): 24372.
- Dai H, Zhu L, Pan B, et al. The relationship between serum γ-glutamyltransferase (GGT) and diabetic nephropathy in patients with type 2 diabetes mellitus: a cross-sectional study. Clin Exp Med. 2023; 23(7): 3619–3630.
- Gray B, Muhlhausler BS, Davies PS, et al. Liver enzymes but not free fatty acid levels predict markers of insulin sensitivity in overweight and obese, nondiabetic adults. Nutr Res. 2013; 33(10): 781–788.
- Lee DH, Blomhoff R, Jacobs D. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radical Research. 2004; 38(6): 535–539.
- Lee DH, Jacobs DR, Gross M, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003; 49(8): 1358–1366.
- Daenen K, Andries A, Mekahli D, et al. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019; 34(6): 975–991.
- Su H, Wan C, Song A, et al. Oxidative Stress and Renal Fibrosis: Mechanisms and Therapies. Adv Exp Med Biol. 2019; 1165: 585–604.
- Yilmaz MI, Turgut F, Kanbay M, et al. Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease. Int Urol Nephrol. 2013; 45(4): 1071–1078.
- Khaira A, Mahajan S, Kumar A, et al. Endothelial function and oxidative stress in chronic kidney disease of varying severity and the effect of acute hemodialysis. Ren Fail. 2011; 33(4): 411–417.
- Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016; 36(12): 1723–1734.
- Corti A, Belcastro E, Dominici S, et al. The dark side of gamma-glutamyltransferase (GGT): Pathogenic effects of an 'antioxidant' enzyme. Free Radic Biol Med. 2020; 160: 807–819.
- Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004; 38(6): 535–539.
- Shen ZW, Xing J, Wang QL, et al. Association between serum γ-glutamyltransferase and chronic kidney disease in urban Han Chinese: a prospective cohort study. Int Urol Nephrol. 2017; 49(2): 303–312.